251111-15-6
Chemical Structure
CKD-731
- CAS. Nr.: 251111-15-6
- Formula:C28H38O8
- Molecular Weight:502.60
IUPAC Name: (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (E)-3-(3,4,5-trimethoxyphenyl)acrylate
InChIKey: YALIVVKJRYVKNB-GGHPKCFRSA-N
SMILES: O=C(O[C@H](CC1)[C@@H](OC)[C@H]([C@@]2(C)O[C@@H]2C/C=C(C)\C)[C@]31CO3)/C=C/C4=CC(OC)=C(OC)C(OC)=C4
Biological Activity: CKD-731 is a MetAP2 inhibitor (IC50 = 0.96 nM) that inhibits methionine aminopeptidase 2 through covalent binding to His-231 and inhibits endothelial cell growth and proliferation. CKD-731 has poor aqueous solubility and can be used in cancer research[1][2][3][4][5][6][7].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CKD-731 | CKD-731 is a MetAP2 inhibitor (IC50 = 0.96 nM) that inhibits methionine aminopeptidase 2 through covalent binding to His-231 and inhibits endothelial cell growth and proliferation. CKD-731 has poor aqueous solubility and can be used in cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chun E, et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. International journal of cancer. 2005 Mar 10;114(1):124-30. [Content Brief]
- [2]. Fardis M, et al. Design, synthesis and evaluation of a series of novel fumagillin analogues. Bioorganic & medicinal chemistry. 2003 Nov 17;11(23):5051-8.
- [3]. Kwon HJ, et al. Chemical genomics-based target identification and validation of anti-angiogenic agents. Current medicinal chemistry. 2003 May;10(9):717-36.
- [4]. Kwon H J. Chemical Genomics-Based Target Mining and Validation of Biologically Active Small Molecules[J]. Frontiers in Medicinal Chemistry-Online, 2005, 2(1): 417-430.
- [5]. Yin SQ, et al. The development of MetAP-2 inhibitors in cancer treatment. Current medicinal chemistry. 2012;19(7):1021-35. [Content Brief]
- [6]. Sendzik M, et al. Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth. Bioorganic & medicinal chemistry letters. 2004 Jun 21;14(12):3181-4.
- [7]. Bradshaw, R. A. (2004). Methionine aminopeptidase 2 inhibition: antiangiogenesis and tumour therapy. Expert Opinion on Therapeutic Patents, 14(1), 1-6.
